Thank you very much, Madam Chair.
Good morning, Dr. Gauthier. Welcome to all of you.
I want to understand your second recommendation on the changes you would like us to make to the Patent Act regarding pharmaceuticals. I understand from your recommendation that where research on prevention is concerned, more time is needed to study the effectiveness of a molecule. Under the current Patent Act, the protection could expire before the medication was marketed or studied in clinical trials.
Have I understood your recommendation correctly? Could it be applied to something else besides Alzheimer's disease?